Context Therapeutics Stock Market Value
| CNTX Stock | USD 1.52 0.02 1.33% |
| Symbol | Context |
Context Therapeutics Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Context Therapeutics. If investors know Context will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Context Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.88) | Return On Assets (0.19) | Return On Equity (0.30) |
The market value of Context Therapeutics is measured differently than its book value, which is the value of Context that is recorded on the company's balance sheet. Investors also form their own opinion of Context Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Context Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Context Therapeutics' market value can be influenced by many factors that don't directly affect Context Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Context Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Context Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Context Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Context Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Context Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Context Therapeutics.
| 11/01/2024 |
| 12/01/2024 |
If you would invest 0.00 in Context Therapeutics on November 1, 2024 and sell it all today you would earn a total of 0.00 from holding Context Therapeutics or generate 0.0% return on investment in Context Therapeutics over 30 days. Context Therapeutics is related to or competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, X4 Pharmaceuticals, Spero Therapeutics, and Bolt Biotherapeutics. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for... More
Context Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Context Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Context Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 23.32 | |||
| Value At Risk | (7.76) | |||
| Potential Upside | 5.38 |
Context Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Context Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Context Therapeutics' standard deviation. In reality, there are many statistical measures that can use Context Therapeutics historical prices to predict the future Context Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.69) | |||
| Total Risk Alpha | (1.41) | |||
| Treynor Ratio | (1.27) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Context Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Context Therapeutics Backtested Returns
Context Therapeutics secures Sharpe Ratio (or Efficiency) of -0.13, which signifies that the company had a -0.13% return per unit of risk over the last 3 months. Context Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Context Therapeutics' Mean Deviation of 3.36, risk adjusted performance of (0.09), and Standard Deviation of 4.68 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.5, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Context Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Context Therapeutics is expected to be smaller as well. At this point, Context Therapeutics has a negative expected return of -0.63%. Please make sure to confirm Context Therapeutics' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Context Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.63 |
Good predictability
Context Therapeutics has good predictability. Overlapping area represents the amount of predictability between Context Therapeutics time series from 1st of November 2024 to 16th of November 2024 and 16th of November 2024 to 1st of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Context Therapeutics price movement. The serial correlation of 0.63 indicates that roughly 63.0% of current Context Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.63 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Context Therapeutics lagged returns against current returns
Autocorrelation, which is Context Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Context Therapeutics' stock expected returns. We can calculate the autocorrelation of Context Therapeutics returns to help us make a trade decision. For example, suppose you find that Context Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Context Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Context Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Context Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Context Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Context Therapeutics Lagged Returns
When evaluating Context Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Context Therapeutics stock have on its future price. Context Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Context Therapeutics autocorrelation shows the relationship between Context Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Context Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.